Explainers
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on IDT Australia.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Patrys wins fresh grant, IDT does not and Next Science is off to sell stuff in Canada
Health & Biotech
Who got what in the healthcare budget, and which ASX stocks could benefit
Health & Biotech
Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021
Health & Biotech
ASX Health Stocks: ImpediMed extends SOZO contract with global pharma AstraZeneca
Health & Biotech
Check Up: Moderna trials mRNA-based HIV vaccine, while these ASX biotechs get patents
Health & Biotech
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
Health & Biotech
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
Health & Biotech
What’s the best pot stock of 2021? And who’s targeting market domination in 2022?
Health & Biotech
IDT falls 40pc after Morrison government rejection; what now for the company’s COVID vaccine manufacturing ambitions?
News
ASX Small Cap Lunch Wrap: It’s not rocket surgery
Health & Biotech
ASX Health Stocks: CSL drags Healthcare index down 5pc on a mammoth $6.3bn cap raise
News
10 at 10: These ASX stocks are flying high once more this morning
Health & Biotech
ScoPo’s Powerplays: IDT wins big on COVID vaccines, but Healthcare IPOs look exhausted
News
Closing Bell: Lithium debut goes up, health stock debut gets smashed
Health & Biotech
ScoPo’s Powerplays: As focus turns to Delta variant, these ASX health stocks are profiting from COVID-19 testing
News
Closing Bell: ASX retreats, led by 2pc drop in energy
Health & Biotech